Furthermore, the C-23 hydroxyl group of alisol B can also be esterified by a variety of carboxylic acids with anti-inflammatory and lipid-lowering activities (such as ferulic acid, caffeic acid, chlorogenic acid) to design a panel of novel ester-bearing prodrugs with dual biological functions (such as lipid-lowering and FXR agonist effect), to develop novel prodrugs for treating NAFLD or obesity-related metabolic disorders. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.